Baxter International ended 2024 on a positive note, overcoming challenges posed by Hurricane Helene and delivering better-than-expected Q4 results. The success of the Novum IQ infusion pump ...

Following the completion of a massive restructuring plan, the medical equipment giant projects 4% to 5% sales growth this year.

This positive performance was partly attributed to the successful launch of the Novum IQ infusion pump, which contributed to a 50% growth in the infusion business. Looking ahead, Baxter has ...

Baxter International Inc. ( NYSE: BAX) Q4 2024 Earnings Conference Call February 20, 2025 8:30 AM ET Clare Trachtman - SVP and Chief IRO Brent Shafer - Chairman, and Interim CEO Heather Knight - COO ...

primarily driven by the demand for the Novum IQ platform. Despite operational challenges due to Hurricane Helene, Baxter anticipates a resumed production of IV solutions by late November.

Baxter International Inc (BAX) reports robust earnings growth and outlines strategic priorities for 2025 despite facing operational challenges.